Safety of Nicotinamide Riboside Injections: Clinical Findings
Objectives
To assess intravenous, sub-Q, or IM NR injection tolerability and monitor adverse events, vital signs, and laboratory safety measures.
Journal
medRxiv
Key Outcomes
- Across both studies, NR injections were generally well-tolerated, with no serious treatment-related adverse events, other than typical injection-site discomfort.
- Preliminary signals around reductions in systolic blood pressure, inflammation, and blood glucose were observed, but are too early to draw conclusions from and require larger, placebo-controlled studies to validate.
- At-home subcutaneous self-injection was shown to be feasible under protocol-defined conditions—a notable finding for the field.
Duration
Study 1:
- Intravenous, subcutaneous, or intramuscular injection once daily for 3 consecutive days
Study 2:
- Phase I: Intramuscular or subcutaneous injection once daily for 3 days
- Phase II: Subcutaneous injection three times per week for 90 days
Dose
- Study 1: 100 mg NR or NAD+*
- Study 2: 50 or 100 mg NR**
*Dissolved in 2 mL bacteriostatic water
**Reconstituted from sterile powder (500 mg multi-use vial) with bacteriostatic water
Study Design
- Study 1: Randomized, double-blind, placebo-controlled, parallel assignment study in 45 overweight or obese adults with mild-to-moderate self-reported fatigue
- Study 2: Randomized, open-label, two-phase study in 39 healthy adults with some degree of fatigue